Incyte Corporation

Incyte Corporation

INCY

$117.59

Updated: 04/11/2026, 11:09:14

Market Cap
$23.97B
Sector
Healthcare
Industry
Biotechnology
Country
US

No historical data available

Company Profile

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

USD
NASDAQ
CEO: William J. Meury
Employees: 2,844
https://www.incyte.com
Asset Summaries
Latest generated summaries for INCY

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
INCY-10-k-fy2025.html2.2 MBtext/htmlENFiled 10/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 56 KPI observations

Revenue

$5.1B

FY 2025 · Reported

Net income

$1.3B

FY 2025 · Reported

Gross margin

92.8%

FY 2025 · Calculated

Free cash flow

N/A

FY — · Reported

R&D intensity

39.9%

FY 2025 · Calculated

Share repurchases

$2.0B

FY 2024 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Approved products
Commercial and pipeline product portfolio
Estimated minimum market exclusivity dates
Additional patent expiry dates

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Global biopharmaceutical company

Global biopharmaceutical company; HQ Wilmington, Delaware

99%
Source evidence
“Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware”

Company description

Incyte is a biopharmaceutical company engaged in discovery, development, formulation, manufacturing and commercialization of drug products and drug candidates.

95%
Source evidence
“the discovery, development, formulation, manufacturing and commercialization of our compounds, our drug candidates and JAKAFI®/JAKAVI® (ruxolitinib)”

Outsourced small molecule manufacturing model

No internal facilities for small molecule commercial production; fully outsourced to third parties; biologics combine internal (Yverdon) and third-party manufacturing

95%
Source evidence
“We currently do not operate manufacturing facilities for clinical or commercial production of JAKAFI, ICLUSIG, PEMAZYRE and OPZELURA.”

Three therapeutic areas

Hematology, Oncology, and Inflammation and Autoimmunity (IAI)

99%
Source evidence
“These therapeutic areas are: Hematology, Oncology, and Inflammation and Autoimmunity (“IAI”).”

Approved products

JAKAFI, ICLUSIG, PEMAZYRE, OPZELURA, MINJUVI, MONJUVI, ZYNYZ, NIKTIMVO (co-commercialized)

99%
Source evidence
“Our approved products are JAKAFI (ruxolitinib), ICLUSIG (ponatinib), PEMAZYRE (pemigatinib), OPZELURA (ruxolitinib cream), MINJUVI (tafasitamab), MONJUVI (tafasitamab-cxix) and ZYNYZ (retifanlimab-dlwr), as well as NIKTIMVO (axatilimab-csfr) which is co-commercialized.”

Commercial and pipeline product portfolio

Commercial products include JAKAFI/JAKAVI (ruxolitinib), PEMAZYRE, ICLUSIG, MONJUVI/MINJUVI, OPZELURA cream, ZYNYZ, NIKTIMVO; pipeline includes ruxolitinib XR and povorcitinib.

95%
Source evidence
“JAKAFI®/JAKAVI® (ruxolitinib), PEMAZYRE® (pemigatinib), ICLUSIG® (ponatinib), MONJUVI® (tafasitamab-cxix) / MINJUVI® (tafasitamab), OPZELURA® (ruxolitinib) cream, ZYNYZ® (retifanlimab-dlwr) and NIKTIMVOTM (axatilimab)”

Estimated minimum market exclusivity dates

Estimated minimum market exclusivity (US/EU/Japan): JAKAFI 2028/2028/2028; OPZELURA 2028/2028/2028; OLUMIANT 2032/2032/2034; TABRECTA 2032/2032/2032; PEMAZYRE 2035/2036/2036; ICLUSIG -/2028/-; ZYNYZ 2036/2036/2036; MONJUVI 2033/2032/2027; NIKTIMVO 2036/2034/2034; ruxolitinib XR 2028/-/-; povorcitinib 2034/2034/2034.

90%
Source evidence
“The following table sets forth the year in which the basic exclusivity loss is currently estimated to occur in the United States, the European Union, and Japan”

Additional patent expiry dates

Additional Orange-Book/related patent expiries include OPZELURA US patents to 2040 (atopic dermatitis and vitiligo) and povorcitinib patents to 2039.

85%
Source evidence
“Patents are also issued in the US for the treatments of atopic dermatitis and vitiligo with expiration dates of 2040.”

US and Europe government payor discount exposure

Product revenues reduced by US Medicaid/Medicare Part D rebates and mandated discounts in Europe

93%
Source evidence
“such as the Medicaid Drug Rebate Program and Medicare Part D prescription drug coverage reimbursements in the United States and mandated discounts in Europe”

Operations and dependencies

Office locations

Global HQ Wilmington DE; European HQ Morges, Switzerland; Japanese HQ Tokyo; Canadian HQ Montreal

98%
Source evidence
“our European headquarters in Morges, Switzerland, and our other offices across Europe, as well as our Japanese headquarters in Tokyo and our Canadian headquarters in Montreal”

Yverdon, Switzerland large molecule facility

Large molecule production facility in Yverdon, Switzerland with GMP license since June 2022; produces MONJUVI/MINJUVI drug substance

95%
Source evidence
“in June 2022 Swissmedic authorities granted the GMP drug manufacturing license for this facility.”

Headquarters concentration of R&D operations

Most drug discovery and development operations are conducted at headquarters in Wilmington, Delaware; loss of access would negatively impact the business.

95%
Source evidence
“As most of our drug discovery and development operations are conducted at our headquarters in Wilmington, Delaware, the loss of access to this facility would negatively impact our business.”

In-licensing counterparties

Licenses from ARIAD/Takeda, Enable Injections, MacroGenics, Merus, Xencor and Syndax require up-front fees, license fees, milestones and royalties.

95%
Source evidence
“Under these licenses, such as our licenses from ARIAD/Takeda, Enable Injections, MacroGenics, Merus, Xencor and Syndax, we may be required to pay up-front fees, license fees, milestone payments and royalties on sales of future products.”

Single/limited-source reliance for API and drug product

Relies on single or limited qualified third-party manufacturers for API and finished drug product across the portfolio

97%
Source evidence
“We generally have a single source or a limited number of suppliers that are qualified to supply each of the API and finished product of our drug products and our other drug candidates.”

Chinese supply of ruxolitinib raw materials

Raw materials for ruxolitinib phosphate are supplied by Chinese-based companies; a European supplier is expected in production later in 2026

95%
Source evidence
“currently raw materials used to manufacture ruxolitinib phosphate, the API in JAKAFI and OPZELURA, are supplied by Chinese-based companies.”

Ruxolitinib phosphate API supplier count

Three qualified third-party contract manufacturers for ruxolitinib phosphate API

95%
Source evidence
“For ruxolitinib phosphate, the API for JAKAFI and OPZELURA, we have three qualified third-party contract manufacturers from which we can source drug substance.”

Reliance on third-party manufacturers and CROs

Incyte relies on third-party manufacturers, collaborators and clinical research organizations, with risk of drug supply constraints and trial delays.

95%
Source evidence
“Our reliance on others to manufacture our drug products and drug candidates could result in drug supply constraints, delays in clinical trials, increased costs, and withdrawal or denial of regulatory approvals.”

Drug product manufacturing source counts by product

PEMAZYRE has one qualified drug product manufacturer; ZYNYZ and NIKTIMVO one each; MONJUVI two; JAKAFI, ICLUSIG and US OPZELURA two each; OPZELURA ex-US one

90%
Source evidence
“For PEMAZYRE, we have one qualified third-party manufacturer from which we can source commercial drug product.”

Employee base as of December 31, 2025

2,844 employees at year-end 2025, up ~9% from 2,617; 70% in US/Canada, 27% Europe, 3% Asia

97%
Source evidence
“As of December 31, 2025, we had 2,844 employees, representing an increase of approximately 9% over our 2,617 employees as of the end of the prior year.”

Positioning and strategy

MorphoSys tafasitamab rights acquisition

February 2024 purchase agreement with MorphoSys for exclusive global rights to tafasitamab (MONJUVI/MINJUVI)

90%
Source evidence
“in February 2024 we entered into a purchase agreement with MorphoSys AG and MorphoSys US Inc. under which we acquired rights to tafasitamab (MONJUVI/MINJUVI)”

Competitive landscape

Incyte faces intense competition from fully integrated pharmaceutical companies and others with substantially greater resources.

90%
Source evidence
“We face significant competition from organizations, particularly fully integrated pharmaceutical companies, that are pursuing pharmaceuticals that are competitive with our drug products and our drug candidates.”

Collaborations, licensing and acquisitions

Business development via collaborations, licensing milestones/royalties, and acquisitions of complementary products and technologies

95%
Source evidence
“We establish business relationships, including collaborative arrangements with other companies and medical research institutions... We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business”

Collaboration and licensing strategy

Incyte pursues collaborations and in-licensing to expedite development and commercialization and to receive upfront payments, milestones and royalties.

90%
Source evidence
“the potential to expedite the development and commercialization of certain of our compounds, as well as the opportunity to receive upfront payments and future milestones and royalties”

Risks, financing, and outlook

China-US trade dispute exposure on raw materials

A US-China trade dispute or Chinese government actions limiting supply would materially and adversely affect ability to manufacture products

90%
Source evidence
“an international trade dispute between China and the United States or any other actions by the Chinese government that would limit or prevent Chinese companies from supplying these materials would adversely affect our ability to manufacture and supply our products”

IRA Medicare Part D Discount Program changes effective 2025

IRA Part D changes effective 2025; Incyte exempt from negotiation through 2028 on qualifying drugs; 2025 Part D sales allowance reduction

96%
Source evidence
“The Inflation Reduction Act includes certain exemptions for small biotech drug manufacturers, including Incyte. These exemptions apply on a drug-specific basis, and qualifying drugs will be exempt from possible negotiation through 2028”

EU GDPR fines up to €20 million or 4% of annual global revenue

GDPR noncompliance fines can reach €20 million or 4% of annual global revenue, whichever is greater.

95%
Source evidence
“in the EU under the General Data Protection Regulation, potential fines for noncompliance are up to €20 million or 4% of annual global revenue, whichever is greater.”

HIPAA data privacy exposure

Data privacy incidents could trigger liability or sanctions under HIPAA and other data privacy laws.

90%
Source evidence
“liability or sanctions under data privacy laws, including healthcare laws such as the Health Insurance Portability and Accountability Act”

Healthcare compliance scrutiny including prior inquiry

Previously subject to inquiry regarding speaker programs and patient assistance programs; violations could mean fines and exclusion from Medicare/Medicaid

85%
Source evidence
“we have previously been subject to an inquiry relating to our speaker programs and patient assistance programs.”

Dependence on JAKAFI/JAKAVI

Incyte depends heavily on JAKAFI/JAKAVI (ruxolitinib); loss or decline of these revenues could materially harm the business.

98%
Source evidence
“We depend heavily on JAKAFI/JAKAVI (ruxolitinib), and if we are not able to maintain revenues from JAKAFI/JAKAVI or those revenues decrease, our business may be materially harmed.”

Reliance on Wilmington, Delaware headquarters

Most drug discovery and development conducted at Wilmington, Delaware headquarters; loss of access would negatively impact business

95%
Source evidence
“the loss of access to this facility would negatively impact our business.”

Drug pricing pressure from governments and payors

Pricing pressure from government and private payors threatens product revenues

95%
Source evidence
“Our product revenues also face challenges from economic conditions and drug pricing initiatives driven by governments and private payors.”

America Invents Act review proceedings challenge patent validity

Third parties can challenge issued U.S. patents via AIA review proceedings; invalidation could allow FDA generic approval before patent expiration.

95%
Source evidence
“If we are unsuccessful in these proceedings some or all of our claims in the patents may be narrowed or invalidated and the patent protection for our products and drug candidates in the United States could be substantially shortened.”

Drug pricing and reimbursement risk

Loss of coverage/reimbursement from government and third-party payors, and Medicare/Medicaid drug pricing proposals, could harm results of operations.

95%
Source evidence
“If recent proposals for changes to Medicare and Medicaid reimbursement of drug prices are adopted into law, our results of operations and financial condition could be harmed.”

Geopolitical and macro risk exposure

Business is exposed to geopolitical events (Russian invasion of Ukraine, Middle East conflicts), pandemics, and tariffs/trade conflicts.

90%
Source evidence
“public health pandemics such as the COVID-19 pandemic, natural disasters, or geopolitical events such as the Russian invasion of Ukraine and conflicts in the Middle East”

Artificial intelligence use creates legal and reputational risks

Increasing AI use in biopharma could produce inaccurate analyses, competitive harm, legal liability, and release of confidential proprietary information.

90%
Source evidence
“If the analyses that artificial intelligence applications assist in producing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability, and brand or reputational harm.”

Hatch-Waxman reverse payment settlement uncertainty

Supreme Court ruling that reverse-payment patent settlements are analyzed under rule of reason may make generic patent litigation settlements more difficult.

90%
Source evidence
“settlements involving “reverse payments” from brand-name drug companies to generic drug companies should be analyzed under the rule of reason. This ruling may create uncertainty and make it more difficult to settle patent litigation”

Key personnel dependency without key person insurance

Highly dependent on key employees; does not maintain key person insurance

90%
Source evidence
“We do not maintain “key person” insurance on any of our employees.”

Supply interruption from single-source manufacturers

Single-source supplier failure could cause material clinical or commercial supply interruption; safety stock strategy used to buffer demand changes

90%
Source evidence
“If any of these single source suppliers were to become unable or unwilling to supply us with API or finished product that complies with applicable regulatory requirements, we could incur significant delays in our clinical trials or interruption of commercial supply”

Counterfeit and stolen product risk

Counterfeit versions of products have been distributed using Incyte packaging; reputational and revenue risk

85%
Source evidence
“We are aware that counterfeit versions of our products have been distributed or sold by entities not authorized by us using product packaging suggesting that the product was provided by us.”

Escient Pharmaceuticals acquisition failure

2024 Escient Pharmaceuticals acquisition did not advance; both lead compounds discontinued the same year

85%
Source evidence
“in 2024 we acquired Escient Pharmaceuticals, Inc., but later in that year we stopped development of the two lead compounds acquired from Escient.”

Large molecule production facility risk

Risk of unanticipated delays or issues relating to Incyte's large molecule production facility.

85%
Source evidence
“unanticipated delays or changes in plans or regulatory agency interactions or other issues relating to our large molecule production facility”

Material exposure graph

JAKAFI/JAKAVI (ruxolitinib)
Revenue Exposure

Incyte depends heavily on ruxolitinib revenues; decline would materially harm the business.

Relevance 95·Dependency 90·Confidence 98
Source evidence
“We depend heavily on JAKAFI/JAKAVI (ruxolitinib), and if we are not able to maintain revenues from JAKAFI/JAKAVI or those revenues decrease, our business may be materially harmed.”
JAKAFI (ruxolitinib)
Revenue Exposure

Incyte's revenues depend substantially on JAKAFI; loss of exclusivity in 2028 and competing product launches are direct revenue risks.

Relevance 95·Dependency 90·Confidence 98
Source evidence
“we depend substantially on product revenues from JAKAFI. We must develop and commercialize new products to achieve revenue growth and to offset revenue losses from the loss of product exclusivity of JAKAFI in 2028”
patent exclusivity portfolio
Legal Exposure

Core products lose basic exclusivity starting 2028 (JAKAFI/OPZELURA/ruxolitinib), exposing revenues to generic competition.

Relevance 90·Dependency 85·Confidence 90
Source evidence
“JAKAFI/JAKAVI (ruxolitinib) Estimated Minimum Market Exclusivity Dates 2028 2028 2028”
JAKAFI
Revenue Exposure

JAKAFI supply depends on three qualified API manufacturers and two drug product manufacturers, with ruxolitinib raw materials sourced from China.

Relevance 90·Dependency 75·Confidence 85
Source evidence
“For JAKAFI and ICLUSIG, we have two qualified third-party manufacturers from which we can source commercial drug product.”
third-party manufacturers
Supplier Dependency

Reliance on third-party manufacturers creates risk of drug supply constraints, trial delays, increased costs, and regulatory approval withdrawal.

Relevance 85·Dependency 85·Confidence 95
Source evidence
“Our reliance on others to manufacture our drug products and drug candidates could result in drug supply constraints, delays in clinical trials, increased costs, and withdrawal or denial of regulatory approvals.”
specialty pharmacies and wholesalers
Customer Exposure

Loss of or reduced sales to any one specialty pharmacy or wholesaler could harm operations and financial condition.

Relevance 85·Dependency 80·Confidence 95
Source evidence
“the loss of, or significant reduction in sales to, any one of these specialty pharmacies or wholesalers could harm our operations and financial condition”
US drug pricing / Medicare & Medicaid reimbursement proposals
Regulatory Exposure

Healthcare reform and Medicare/Medicaid drug pricing changes could reduce pricing and profitability of pharmaceuticals.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“Healthcare reform measures could impact the pricing and profitability of pharmaceuticals, and adversely affect the commercial viability of our or our collaborators' products and drug candidates.”
Inflation Reduction Act of 2022 (Part D Discount Program)
Regulatory Exposure

IRA Part D changes require 10%/20% discounts from 2025, but Incyte's small biotech exemptions (negotiation exemption through 2028, phased-in discounts) reduced its 2025 Part D sales allowances.

Relevance 85·Dependency 70·Confidence 95
Source evidence
“In 2025, we saw a reduction in our sales allowances owed under Medicare Part D, due to changes to the Part D Discount Program”
China
Supplier Dependency

Ruxolitinib phosphate raw materials (API for JAKAFI and OPZELURA) are supplied by Chinese-based companies, creating dependency on Chinese supply chains.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“currently raw materials used to manufacture ruxolitinib phosphate, the API in JAKAFI and OPZELURA, are supplied by Chinese-based companies.”
Wilmington, Delaware
Revenue Exposure

Most drug discovery, research, development and marketing activities are concentrated at the Wilmington headquarters; loss of access would interrupt the business.

Relevance 80·Dependency 75·Confidence 90
Source evidence
“Our facility in Wilmington, Delaware is our headquarters and is also where we conduct most of our drug discovery, research, development and marketing activities.”
Supply chain disruption
Supplier Dependency

Single-source and limited-source supplier model means a supplier failure could interrupt clinical trials and commercial supply; long lead times reduce flexibility.

Relevance 80·Dependency 70·Confidence 90
Source evidence
“we may have less flexibility to adjust our supply in response to changes in demand than if we had shorter lead times.”
fully integrated pharmaceutical companies
Competitive Exposure

Competitors with substantially greater resources may commercialize competing products or achieve superior patent/regulatory positions.

Relevance 80·Dependency 65·Confidence 90
Source evidence
“Many companies and institutions... have substantially greater financial resources, larger drug discovery, development and commercial staffs and significantly greater experience”
Government and private payor drug pricing initiatives
Cost Driver

Government and private payor pricing initiatives are an explicit challenge to Incyte's future product revenues.

Relevance 80·Dependency 60·Confidence 93
Source evidence
“Our product revenues also face challenges from economic conditions and drug pricing initiatives driven by governments and private payors.”
in-licensing partners (ARIAD/Takeda, MacroGenics, Merus, Xencor, Syndax, Enable Injections)
Technology Dependency

Key products (retifanlimab from MacroGenics, tafasitamab from Xencor, axatilimab from Syndax) depend on licenses with milestone and royalty obligations.

Relevance 75·Dependency 70·Confidence 90
Source evidence
“Retifanlimab licensed from MacroGenics, Inc.”
FDA and healthcare fraud/abuse regulation
Regulatory Exposure

FDA and foreign agencies regulate critical activities including clinical studies, manufacturing, promotion and distribution; violations could bring fines, penalties and exclusion from Medicare/Medicaid; company previously faced an inquiry into speaker and patient assistance programs.

Relevance 75·Dependency 65·Confidence 85
Source evidence
“Violations of governmental regulation by us, our vendors or donation recipients may be punishable by criminal and civil sanctions, including damages, fines and penalties and exclusion from participation in government programs, including Medicare and Medicaid.”
US-China tensions
Geopolitical Exposure

A China-US trade dispute or Chinese government export actions would block supply of ruxolitinib raw materials, affecting manufacturing and operating results.

Relevance 75·Dependency 55·Confidence 90
Source evidence
“an international trade dispute between China and the United States or any other actions by the Chinese government that would limit or prevent Chinese companies from supplying these materials would adversely affect our ability to manufacture and supply our products to meet market needs”
PBMs, pharmacies and wholesalers
Customer Exposure

Cyber disruption of PBM/pharmacy/wholesaler systems could block claims processing and prescription fulfillment, reducing net product revenues.

Relevance 70·Dependency 65·Confidence 90
Source evidence
“the ability to process claims and fulfill prescriptions could be impacted, which could result in adverse effects on our net product revenues.”
General Data Protection Regulation
Regulatory Exposure

GDPR imposes fines up to €20 million or 4% of annual global revenue for noncompliance with data privacy obligations in the EU.

Relevance 70·Dependency 60·Confidence 95
Source evidence
“in the EU under the General Data Protection Regulation, potential fines for noncompliance are up to €20 million or 4% of annual global revenue, whichever is greater.”
Yverdon, Switzerland
Manufacturing Dependency

Internal biologic drug substance production is concentrated at the Yverdon facility, which manufactures MONJUVI/MINJUVI drug substance.

Relevance 65·Dependency 55·Confidence 90
Source evidence
“The Yverdon facility started to manufacture MONJUVI/MINJUVI drug substance during the fourth quarter of 2022.”
America Invents Act
Legal Exposure

AIA review proceedings increase uncertainty over U.S. patent validity, which could shorten protection and allow generic competition.

Relevance 65·Dependency 55·Confidence 95
Source evidence
“third parties are now able to challenge the validity of issued U.S. patents through various review proceedings; thus rendering the validity of U.S. patents more uncertain.”
CROs and contract manufacturers
Supplier Dependency

Incyte relies on third-party hosted IT systems and vendors including CROs and contract manufacturers; disruption of their business continuity plans could interrupt operations.

Relevance 60·Dependency 55·Confidence 85
Source evidence
“If our business continuity and disaster recovery plans and procedures or those of our vendors, including our CROs and contract manufacturers, were disrupted, inadequate or unsuccessful in the event of a problem, we could experience an interruption of all or a portion of our operations”
geopolitical events and trade conflicts
Geopolitical Exposure

Russian invasion of Ukraine, Middle East conflicts, and tariffs/trade conflicts are cited as risks to the business and clinical trial conduct.

Relevance 55·Dependency 45·Confidence 85
Source evidence
“the impact of tariffs and trade conflicts and the effects of any economic slowdown”
artificial intelligence
Technology Dependency

AI is increasingly used in the biopharmaceutical industry and by attackers; inaccurate AI analyses could cause competitive harm, legal liability, and IP leakage.

Relevance 55·Dependency 40·Confidence 90
Source evidence
“the use of artificial intelligence is increasing in the biopharmaceutical industry. As with many developing technologies, artificial intelligence presents risks and challenges that could affect its further development, adoption, and use, which could affect our business.”
Full company information
Latest profile, trading, valuation, and identifier data stored for INCY.
Share price
$117.59
Market cap
$23.97B
Exchange
NASDAQ
Currency
USD
CEO
William J. Meury
Employees
2,844
IPO date
04/11/1993
Beta
0.782
Last dividend
$0.00
Day range
$117.27 – $121.05
52-week range
$89.25 – $132.60
1-day performance
-2.04%
1-year performance
31.75%
Current drawdown (1Y)
-11.32%
CIK
0000879169
CUSIP
45337C102
ISIN
US45337C1027
Created
07/12/2025, 04:43:36
Last update
04/11/2026, 11:09:14

Track Incyte Corporation with an AI analyst

See which prediction-market events move INCY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to INCY from your Railway `news_articles` table.

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

Business Wire • STOCK • 13/06/2026, 13:15:00

Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

Business Wire • STOCK • 13/06/2026, 08:00:00

Incyte: I Am Moving From Hold To Buy

Seeking Alpha • STOCK • 10/06/2026, 03:01:14

Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B

Zacks Investment Research • STOCK • 09/06/2026, 18:31:16

Incyte (NASDAQ: INCY) Price Target Raised Amid Strategic Acquisition and Pipeline Success

Market Data • Market Data • 08/06/2026, 22:12:36

Incyte Corporation (NASDAQ: INCY) Stock Analysis: Oppenheimer Rating and Strategic Acquisition

Market Data • Market Data • 08/06/2026, 21:05:18

Incyte Corporation (INCY) M&A Call Transcript

Seeking Alpha • STOCK • 08/06/2026, 12:58:33

Incyte to Buy Vega Therapeutics For Up to $2 Billion

WSJ • STOCK • 08/06/2026, 09:34:00

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

Business Wire • STOCK • 08/06/2026, 09:00:00

Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports

Reuters • STOCK • 07/06/2026, 08:11:12

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

Business Wire • STOCK • 04/06/2026, 10:05:00

Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate

Reuters • STOCK • 30/05/2026, 10:02:07